Allos Therapeutics Reports Positive Results From Phase II Study of RSR13 For Non-Small Cell Lung Cancer at ASCO
(PR Newswire)...The rationale for using induction chemotherapy in locally advanced non-small cell lung cancer is that chemotherapy may prevent the growth of systemic disease and, concurrently, reduce the local tumor involvement in the lungs and chest which may then be better treated with surgery,......The Company also announced plans to increase the number of patients enrolled in its ongoing Phase III randomized study of RSR13 combined with standard whole brain radiation therapy versus standard whole brain radiation therapy alone for the treatment of patients with brain metastases.......The Company has initiated its first pivotal Phase 3 trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13....- May 13 7:49 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010513/lasu003.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines